Embed Size (px)
Citation preview
Jim Joyce Chairman, CEO January 9, 2012
My presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced, market acceptance of the Aethlon ADAPT™ system, the Hemopurifier® and other product offerings, regulatory delays, manufacturing delays, and other risks detailed in our sec filings accessible at www. Sec.gov.
We create medical devices to address unmet medical needs in cancer, infectious disease, and other life-threatening conditions
The transition from development-stage to revenue-stage organization
Adaptive Dialysis-like Affinity Platform Technology
Dialysis
Plasmapheresis
Mabs
Lectins
Aptamers
ADAPT
The intersection of medical device technology and affinity drug mechanisms
Effective target separation Target binding is highly selective
No target discrimination Toxicity Limits Dosing
Indiscriminate
Effective separation
High specificity Toxicity ADAPT
The Hemopurifier® An Aethlon ADAPT™ Therapy
Aethlon ADAPT™ therapies seamlessly integrate into the infrastructure of dialysis and CRRT machines located in hospitals in clinics worldwide
Aethlon ADAPT™ therapies provide access to the entire circulatory system
• Rapid real-time access to single or multiple therapeutic targets in as little as 15 minutes
• Adjunct to improve SOC therapy benefit without adding drug toxicity or interaction risks
• Able to address targets beyond the reach of drugs
The future is home based therapy
The Aethlon Hemopurifier®
• The lead Aethlon ADAPT™ treatment candidate
• Broad-spectrum capture of viral pathogens and immunosuppressive exosomes underlying cancer and infectious disease
• Compelling HCV & HIV/AIDS treatment outcomes in ESRD patient population
• The Drug Industry
• Provides medical device pathway for affinity drug agents
• $5 million vs. $500 million
• Repurposes approved, clinical stage & previous clinical dropouts
• Military & Government Health Agencies
• Seeking innovative therapeutic solutions
!"#
$!"#
%!"#
&!"#
'!"#
(!"#
)!"#
*!"#
+!"#
,!"#
$!!"#
!# $# %# &# '# (# )# *#
!"#$
%&'(")*+
"+%,'("-.'
/"
0%12"3/'456"
Viral Load Reduction by Drugs Alone
!"#
$!"#
%!"#
&!"#
'!"#
(!"#
)!"#
*!"#
+!"#
,!"#
$!!"#
!# $# %# &# '# (# )# *#
!"#$
%&'(")*+
"+%,'("-.'
/"
0%12"3/'456"
Viral Load Reduction by Hemopurifier Alone
!"#
$!"#
%!"#
&!"#
'!"#
(!"#
)!"#
*!"#
+!"#
,!"#
$!!"#
!# $# %# &# '# (# )# *#
!"#$
%&'(")*+
"+%,'("-.'
/"
0%12"3/'456"
-.#/0123#45#'607/89# :0123#8;.<=#>0=/?@A=/#
:0123#B#45#'60#>0=/?@A=/# :0123#8;.<=#.C3#
Viral Load Reduction by Drugs and Hemopurifier in Combination
0
1000000
2000000
3000000
4000000
5000000
6000000
7000000
Day 1 Pre 3 post 7 post D-10 D-14 D-17 D-21 D-24 30 post
Vira
l Loa
d ul
/ml
Day
Comparasion to RVR Achievement
SOC Alone
SOC + Hemopurifier®
Contact Jim Joyce
Chairman, CEO
8910 University Center Lane
San Diego, California 92122
858.459.7800 x301
